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The kininogenase activities of mouse (mK1), rat (rK1) and human
(hK1) tissue kallikreins were assayed with the bradykinin-con-
taining synthetic peptides Abz-MTEMARRPPGFSPFRSVTVQ-
NH2 (where Abz stands for o-aminobenzoyl) and Abz-MTS-
VIRRPPGFSPFRAPRV-NH2, which correspond to fragments
Met374-Gln393 and Met375-Val393 of mouse and rat LMWKs (low-
molecular-mass kininogens) with the addition of Abz. Bradykinin
was released from these peptides by the mK1- and rK1-mediated
hydrolysis of Arg–Arg and Arg–Ser (or Arg–Ala) peptide bonds.
However, owing to preferential hydrolysis of Phe–Arg compared
with the Arg–Ala bond in the peptide derived from rat LMWK,
hK1 released bradykinin only from the mouse LMWK fragment
and preferentially released des-[Arg9]bradykinin from the rat
LMWK fragment (Abz-MTSVIRRPPGFSPFRAPRV-NH2). The
formation of these hydrolysis products was examined in more de-
tail by determining the kinetic parameters for the hydrolysis of
synthetic, internally quenched fluorescent peptides containing six
N- or C-terminal amino acids of bradykinin added to the five
downstream or upstream residues of mouse and rat kininogens res-
pectively. One of these peptides, Abz-GFSPFRAPRVQ-EDDnp
(where EDDnp stands for ethylenediamine 2,4-dinitrophenyl),
was preferentially hydrolysed at the Phe–Arg bond, confirming
the potential des-[Arg9]bradykinin-releasing activity of hK1 on
rat kininogen. The proline residue that is two residues upstream
of bradykinin in rat kininogen is, in part, responsible for this
pattern of hydrolysis, since the peptide Abz-GFSPFRASRVQ-
EDDnp was preferentially cleaved at the Arg–Ala bond by hK1.
Since this peptidase accepts the arginine or phenylalanine residue
at its S1 subsite, this preference seems to be determined by the
prime site of the substrates. These findings also suggested that
the effects observed in rats overexpressing hK1 should consi-
der the activation of B1 receptors by des-[Arg9]bradykinin. For
further comparison, two short internally quenched fluorescent
peptides that bind to hK1 with affinity in the nM range and some
inhibitors described previously for hK1 were also assayed with
mK1 and rK1.
Key words: bradykinin, fluorescent peptide, inflammation, inhi-
bitor, kallikrein, protease.
INTRODUCTION
Tissue kallikreins constitute a subgroup of serine proteases that
share significant homology with true-tissue kallikrein, encoded
by the KLK1 gene [1,2]. Human true-tissue kallikrein, hK1 (EC
3.4.21.35), is a member of a family of 15 related serine proteases,
including two enzymes expressed in prostate, namely prostate-
specific antigen (hK3) and a trypsin-like enzyme hK2. These pro-
teases share a significant degree of sequence and structural simi-
larities and the genes are clustered together at one locus at least in
three species, namely mouse, rat and human [3–6]. Despite their
highly conserved structures, their known or predicted peptidase
functions are specific and distinct from one another, and their
wide range of expression patterns indicates their involvement
in diverse physiological processes [2,7,8]. Phylogenetic analyses
show that tissue kallikrein genes emerged after the separation of
primate and rodent lineages; therefore, the independent evolution
of tissue kallikrein genes in rodents and humans indicates that the
corresponding serine proteases expressed by these genes could
be involved in biological processes specific for each species [9–
11]. The proteases can present peptidase specificities that are
also particular for each species. Human tissue kallikrein hK1
has the best-established functions, which include release of Lys-
bradykinin (kallidin) in inflammatory processes such as arthritis,
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7-amide; Pac, phenyl-acetyl; PKSI-527, trans-4-aminomethylcyclohexanecarbonyl-L-phenylalanine-4-carboxymethylanilide.
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asthma and rhinitis [12–14] and the processing of hormone and
other peptide precursors [2,15]. hK1 releases Lys-bradykinin by
limited proteolysis of high- and low-molecular-mass kininogens
by cleavage at the Met379-Lys380 and Arg389-Ser390 bonds [16].
Rat tissue kallikrein, rK1, cleaves a Lys–Arg bond and generates
bradykinin from bovine and rat kininogens [17,18], and mouse
submandibular tissue kallikrein also releases bradykinin from
bovine [19] and mouse [20] kininogens.
Little is known about the species specificity of tissue kallikrein–
kininogen interaction and the specificity of tissue kallikrein from
animals used as model for the study of the kallikrein–kinin
system. The mouse model was used for assays of hK1 inhibitors
[21], for knockout of mouse tissue kallikrein mK1 [22] and for
overexpression of hKLK1 in a transgenic hypotensive lineage. A
rat model for gene therapy of hypertension was used to assess
the effects of administration of the human kallikrein gene, either
in the form of naked DNA or in an adenovirus vector [23,24]. In
addition, the hypotensive effect of the expression of hKLK1 was
demonstrated in a transgenic rat lineage [25].
To characterize the inter-species specificities of mK1, rK1 and
hK1, we describe in the present study the activities of these pro-
teases on the synthetic peptides Abz-MTEMARRPPGFSPFRSV-
TVQ-NH2 (where Abz stands for o-aminobenzoyl) and Abz-MT-
SVIRRPPGFSPFRAPRV-NH2, which correspond to fragments
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Met374-Gln393 and Met375-Val393 of mouse (SwissProt accession
no. 008677) and rat [27] low-molecular-mass kininogens. These
two peptides span the bradykinin sequence in these kininogens.
The fluorescent marker Abz was added at the N-terminal end of
each peptide. Release of bradykinin from these two peptides re-
quires the hydrolysis of Arg–Arg and Arg–Ser (or Arg–Ala)
peptide bonds. The hydrolysis of these peptide bonds in mouse
and rat kininogens for the release of bradykinin by mK1 and rK1
was examined in more detail by determining the kinetic para-
meters for the hydrolysis of internally quenched fluorescent pep-
tides containing the six C-terminal amino acids of bradykinin
added to the six upstream residues of mouse (Abz-GFSPFRSV-
TVQ-EDDnp, where EDDnp stands for ethylenediamine 2,4-
dinitrophenyl) and rat (Abz-GFSPFRAPRVQ-EDDnp) kinino-
gens. Similarly, two other peptides were synthesized, i.e. those
containing the two N-terminal amino acids of bradykinin added to
six downstream residues of mouse (Abz-MTEMARRPQ-EDDnp)
and rat (Abz-MTSVIRRPQ-EDDnp) kininogens.
For further comparison with hK1, two peptidyl-MCA substrates
(where MCA stands for 4-methylcoumarin-7-amide), described
previously for hK1, two short internally quenched fluorescent
peptides that bind to hK1 with nM affinity and some inhibitors
described previously for hK1 [28–31] were also assayed with
mK1 and rK1.
MATERIALS AND METHODS
Peptides
All the intramolecularly quenched fluorogenic peptides that con-
tain EDDnp attached to glutamine residue were obtained by
the solid-phase peptide synthesis method, details of which are
available in [32]. An automated bench-top simultaneous multiple
solid-phase peptide synthesizer (PSSM 8 system; Shimadzu,
Kyoto, Japan) was used for the solid-phase synthesis of all the
peptides by the Fmoc (fluoren-9-ylmethoxycarbonyl) procedure.
The short internally quenched fluorescent peptides were obtained
by synthesis in solution [28]. The final deprotected peptides were
purified by semipreparative HPLC using an Econosil C18 column
(10 µm; 22.5 mm × 250 mm) and the following two-solvent
system: solvent A, trifluoroacetic acid/water (1:1000) and solvent
B, trifluoroacetic acid/ACN (acetonitrile)/water (1:900:100). The
column was eluted at a flow rate of 3 or 5 ml/min with a 10–50
or 30–60% gradient of solvent B for 30 or 45 min. Analytical
HPLC was performed using a binary HPLC system (Shimadzu)
equipped with an SPD-10AV Shimadzu UV–Visible detector and
a Shimadzu RF-535 fluorescence detector, coupled with an Ul-
trasphere C18 column (5 µm, 4.6 × 250 mm), which was eluted
with solvent systems A1 (H3PO4/water, 1:1000) and B1 (ACN/
water/H3PO4, 900:100:1) at a flow rate of 0.8 ml/min and a 10–
80% gradient of B1 for 15 min. The HPLC column eluates were
monitored by their absorbance A220 and by fluorescence emission
at 420 nm following excitation at 320 nm. The molecular mass
and purity of the synthesized peptides were examined by MALDI–
TOF-MS (matrix-assisted laser-desorption ionization–time-of-
flight MS; TofSpec-E; Micromass, Manchester, U.K.) and/or pep-
tide sequencing using a protein sequencer PPSQ-23 (Shimadzu,
Tokyo, Japan). The concentrations of the substrate solutions were
determined by colorimetric measurement of the Dnp (2,4-dinitro-
phenyl) group (molar absorption coefficient of 17 300 M−1 · cm−1
at 365 nm).
Enzymes
Mouse true-tissue kallikrein mK1 (originally reported as pro-
teinase F [33] and later identified as mK1 [19]) was purified from
the submandibular glands of 52 female mice (ICR strain) by the
procedure described in [33]. The purified enzyme had a specific
activity similar to that reported previously and was 90–95% pure
when it was analysed by reverse-phase HPLC. The purified en-
zyme was dissolved in 1 mM HCl and stored at − 80 ◦C with
minimum repetition of freezing and thawing. Homogeneous pre-
parations of human tissue kallikrein, obtained by the method of
Shimamoto et al. [34], and rat tissue kallikrein, obtained as des-
cribed previously [35], were kindly provided by Dr J. Chao (Medi-
cal University of South Carolina, Charleston, U.S.A.). The molar
concentrations of enzyme solutions were determined by active-site
titration with 4-methylumbelliferyl-p-guanidinobenzoate [36].
Enzyme hydrolysis of fluorescent-quenched substrates
Kinetic assays
Fluorogenic peptidyl substrates were hydrolysed under the fol-
lowing conditions: 20 mM (for hK1) or 50 mM (for rK1 and
mK1) Tris/HCl and 1 mM EDTA, pH 9 (for hK1) or pH 8.5
(for rK1 and mK1), at 37 ◦C; the reactions were monitored by
measuring the fluorescence changes at λem = 420 nm and λex =
320 nm in a Hitachi F-2500 spectrofluorimeter. The 1 cm path-
length cuvette containing 1 ml of buffer solution + substrate was
placed in a thermostatically controlled cell compartment for
5 min before the addition of the enzyme solution and the increase
in fluorescence with time was continuously recorded for 10 min.
The slope was converted into mol of hydrolysed substrate/
min based on the fluorescence curves of standard peptide solutions
before and after total enzyme hydrolysis. The concentration of the
peptide solutions was determined by colorimetric measurement
of the Dnp group (molar absorption coefficient at 365 nm of
17 300 M−1 · cm−1). The enzyme concentration for the initial
rate determination was chosen at a level intended to hydrolyse
less than 5% of the substrate present. The kinetic parameters
were calculated by the method of Wilkinson [37] as well as by
using Eadie–Hofstee plots. All the results obtained were fitted to
non-linear least-squares equations using Grafit version 3.0 from
Erithacus Software (Horley, Surrey, U.K.). The S.D. of Km and kcat
determinations were in no case higher than 6% of the obtained
value.
Determination of the cleavage point in the assayed substrates
The cleaved bonds were identified by isolation of the fragments by
HPLC and the retention times of the fluorescent Abz-containing
fragments were compared with authentic synthetic sequences
and/or by amino acid sequencing. All the fragments were also
checked by MALDI–TOF-MS.
RESULTS AND DISCUSSION
Release of kinins from the bradykinin-containing peptide
fragments of mouse and rat kininogens by mK1, rK1 and hK1
The Met374–Gln393 fragment of mouse kininogen (Abz-MTEM-
ARRPPGFSPFRSVTVQ-NH2) was hydrolysed by mK1 first at
the Arg–Ser bond, accumulating the fragment Abz-MTEMARR-
PPGFSPFR, which was then hydrolysed at the Arg–Arg bond
at a lower rate with the release of bradykinin (RPPGFSPFR).
Figure 1 shows the time course of these reactions as monitored
by HPLC and MS. The fragment Met375–Val393 of rat kininogen
(Abz-MTSVIRRPPGFSPFRAPRV-NH2) was hydrolysed by rK1
in a similar pattern; the Arg–Ala bond was hydrolysed quickly,
and the Arg–Arg bond in Abz-MTSVIRRPPGFSPFR was cleaved
more slowly to release bradykinin (see Figure 2). The rat kinino-
gen fragment was also hydrolysed by mK1, producing bradykinin
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Figure 1 Time course of hydrolysis by mK1 of the mouse kininogen
fragment, Abz-MTEMARRPPGFSPFRSVTVQ-NH2
Each product was isolated and characterized by MALDI–TOF-MS. () Abz-MTEMARRPPGF-
SPFRSVTVQ-NH2 is the substrate that is rapidly hydrolysed forming (H17009) Abz-MTEMARRP-
PGFSPFR, which is slowly hydrolysed to () Abz-MTEMAR or bradykinin (superimposed).
The substrate and their products of hydrolysis were quantified by HPLC and are shown as
percentage of product formation or substrate degradation. Analytical HPLC conditions were: an
Ultrasphere C18 column (5 µm, 4.6 × 250 mm) which was eluted with the solvent systems A1
(H3PO4/water, 1:1000) and B1 (ACN/water/H3PO4, 900:100:1) at a flow rate of 0.8 ml/min and
a 10–80 % gradient of B1 for 15 min. The HPLC column eluates were monitored by their A 220
and by fluorescence emission at 420 nm following excitation at 320 nm. Hydrolysis conditions
were: 50 mM Tris/HCl (pH 8.5), 1 mM EDTA, 37 ◦C, [mK1] = 64 nM, [substrate] = 37 µM.
Figure 2 Time course of hydrolysis by rK1 of the rat kininogen fragment
Abz-MTSVIRRPPGFSPFRAPRV-NH2
Each product was isolated and characterized by MALDI–TOF-MS. () Abz-MTSVIRRPPGFSP-
FRAPRV-NH2 is the substrate that is rapidly hydrolysed forming (H17009) Abz-MTSVIRRPPGFSPFR,
which is slowly hydrolysed to () Abz-MTSVIR or bradykinin (superimposed). All the peptides
were quantified by HPLC (conditions are described in the legend to Figure 1) and are shown
as percentage of their formation or substrate degradation. Hydrolysis conditions were: 50 mM
Tris/HCl (pH 8.5), 1 mM EDTA, 37 ◦C, [rK1] = 7 nM, [substrate] = 37 µM.
with a similar time course (results not shown). hK1 released brady-
kinin from the mouse kininogen fragment (Abz-MTEMARRP-
PGFSPFRSVTVQ-NH2), but preferentially released des-[Arg9]
bradykinin from rat kininogen (Abz-MTSVIRRPPGFSPFRAP-
RV-NH2) as shown in Figure 3. We were surprised to find that
hK1 preferentially cleaved the Phe–Arg bond compared with
the Arg–Ala bond, resulting in the formation of higher amounts
of des-[Arg9]bradykinin than bradykinin. This observation was
Figure 3 Time course of hydrolysis by hK1 of the rat kininogen fragment
Abz-MTSVIRRPPGFSPFRAPRV-NH2
Each peak was isolated and characterized by MALDI–TOF-MS. Only the UV recording is pre-
sented. Top panel: reaction time = time zero; only the UV peak of Abz-MTSVIRRPPGFSPFRA-
PRV-NH2 was detected. Middle panel: reaction time = 15 min; the UV peaks of the products
of hydrolysis Abz-MTSVIRRPPGFSPFR-OH and Abz-MTSVIRRPPGFSPF-OH and the small
amount of residual substrate were detected. Bottom panel: reaction time = 3 h; Abz-MTSVIR-
OH, RPPGFSPFR (bradykinin, BK) and RPPGFSPFR (des-[Arg9]bradykinin) and the residual
fragments Abz-MTSVIRRPPGFSPFR-OH and Abz-MTSVIRRPPGFSPF-OH of the first hydrolysis
were detected. Hydrolysis conditions were: 20 mM Tris/HCl (pH 9.0), 1 mM EDTA, 37 ◦C,
[hK1] = 40 nM and [substrate] = 20 µM. HPLC conditions were the same as described in
Figure 1.
confirmed by the preferred cleavage of the Phe–Arg bond by
hK1 in the peptide Abz-GFSPFRAPRVQ-EDDnp (Table 1), an
internally quenched fluorescent peptide containing the ten C-
terminal amino acids of Abz-MTSVIRRPPGFSPFRAPRV-NH2.
Hydrolysis at the Phe–Arg bond by hK1 in both peptides was
in accordance with an earlier observation of efficient cleavage
after phenylalanine in peptides derived from the reactive-centre
loop of kallistatin [38], which is a specific serpin for hK1, and
in somatostatin [29]. Therefore hK1 is not a restricted arginyl
hydrolase despite its structural similarities to trypsin. In addition,
the hydrolysis at the Phe–Arg bond indicates the acceptance by
hK1 of proline residue at its S2 subsite; this subsite has previously
been demonstrated to accommodate the phenyl side chain of
c© 2004 Biochemical Society
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Table 1 Kinetic parameters for hydrolysis by mK1, rK1 and hK1 of internally quenched fluorescent peptides derived from mouse and rat kininogens and a
short quenched fluorescent substrate containing a pair of basic amino acids
Conditions of hydrolysis: 20 mM (for hK1) or 50 mM (for rK1 and mK1) Tris/HCl and 1 mM EDTA, pH 9 (for hK1) or pH 8.5 (for rK1 and mK1), at 37˚C.
Protease mK1 rK1 hK1 mK1 rK1 hK1
Mouse sequence Abz-GFSPFR↓SVTVQ-EDDnp Abz-MTEMAR↓RPQ-EDDnp
kcat (s−1) 7.0 14.7 3.1 1.49 0.8 0.73
Km (µM) 0.17 2.51 2.1 3.0 6.16 7.35
kcat/Km 41176 5880 1485 496 130 99
Rat sequence Abz-GFSPFR↓APRVQ-EDDnp Abz-MTSVIR↓RPQ-EDDnp
kcat (s−1) 6.6 12.0 * 3.27 5.86 Slow hydrolysis
Km (µM) 0.96 1.47 * 2.40 2.23 Slow hydrolysis
kcat/Km 6948 8163 * 1362 2663 Slow hydrolysis
Short IQF peptide Abz-FR↓R-EDDnp Abz-FR↓K-EDDnp
kcat (s−1) 12.7 18.7 Slow hydrolysis† 18.4 21.8 Slow hydrolysis‡
Km (µM) 0.33 0.2 Slow hydrolysis† 0.77 0.24 Slow hydrolysis‡
kcat/Km 38 697 93 500 Slow hydrolysis† 23 896 90 916 Slow hydrolysis‡
* The peptide Abz-GFSPFRAPRVQ-EDDnp was cleaved at two peptide bonds, R↓A (30 %) and F↓R (70 %) with kcat/Km = 4545.
† Ki = 20 nM.
‡ Ki = 74 nM.
phenylalanine very well [39], which has been considered as a
requisite for a good substrate for tissue kallikreins [40]. The shift
of the cleavage site by hK1 from the Arg–Ala to the Phe–Arg
bond in rat kininogen peptides is probably due to the presence
of the two proline residues upstream of bradykinin in rat kinino-
gen. This directional determinant effect of proline residue can also
explain the release by hK1 of Lys-bradykinin instead of brady-
kinin from human kininogen. In this protein, the sequence at the
N-terminal site of bradykinin is . . . ISLMKRPP . . .; therefore, for
the release of bradykinin, the Lys–Arg bond should be cleaved;
however, the presence of proline residue at the prime site of argi-
nine residue shifts the cleavage to the Met–Lys bond and the re-
lease of Lys-bradykinin. The efficiency of hK1 in cleaving the
Met–Lys bond in peptides spanning the N-terminal side has pre-
viously been shown to be significantly influenced by the P1 ′ −
P3 ′ substrate positions [41]. Consistent with this result, the
hydrolysis of the peptides Abz-GFSPFRAPRVQ-EDDnp and
Abz-GFSPFRASRVQ-EDDnp, presented in Figure 4 and dis-
cussed below, further supports the effect of proline at P2 ′ on the
determination of the site of cleavage, in this case at the Phe–Arg
or Arg–Ala bond. The preferred release of des-[Arg9]bradykinin
by hK1 instead of bradykinin from the synthetic rat kininogen
fragment suggested that the cardiovascular effects observed in
rat overexpressing human kallikrein as models of gene therapy
of hypertension [23–25] should consider the activity of des-
[Arg9]bradykinin on B1 receptors. Although we did not use
purified rat kininogens to verify the release of des-[Arg9]brady-
kinin due to the significant large instability of these proteins, the
synthetic peptides derived from the segments of kininogen that
contain bradykinin sequence have been useful in characterizing
the kininogenase activity of tissue kallikreins such as hK1 [42],
pK1 [43] and hK2 [44]. Previously, we used these kinds of
peptides to characterize the kininogenase activities of cysteine
proteases from Trypanosoma cruzi (cruzipain) [45] and Fasciola
hepatica [46], enzymes that do not belong to the tissue kallikrein
family.
Kinetic parameters for the hydrolysis of fluorescent peptides
To evaluate the kinetic parameters for the hydrolysis of the peptide
bonds cleaved by mK1, rk1 and hK1 in the mouse and rat kinino-
Figure 4 HPLC profile of the fluorescent products of complete hydrolysis
by hK1 of the peptides Abz-GFSPFRAPRVQ-EDDnp and Abz-GFSPFRASRVQ-
EDDnp
The starting substrates were completely hydrolysed after 1 h of incubation with hK1 under the
same conditions as described in Figure 3. Hydrolysis of Abz-GFSPFRASRVQ-EDDnp resulted
in a larger peak of Abz-GFSPFR-OH compared with the hydrolysis of Abz-GFSPF-OH, and the
inverse was observed with the hydrolysis of Abz-GFSPFRAPRVQ-EDDnp.
gen synthetic fragments described above, the internally quenched
fluorescent peptides Abz-MTEMARRPQ-EDDnp, Abz-GFSPF-
RSVTVQ-EDDnp, Abz-MTSVIRRPQ-EDDnp and Abz-GFSP-
FRAPRVQ-EDDnp were synthesized and assayed with the three
kallikreins. As shown in Table 1, mK1 and rK1 hydrolysed
these peptides at the same bonds as cleaved in the bradykinin-
containing fragments of mouse and rat kininogens described
above. The peptides Abz-GFSPFRSVTVQ-EDDnp and Abz-
GFSPFRAPRVQ-EDDnp were hydrolysed more efficiently com-
pared with Abz-MTEMARRPQ-EDDnp and Abz-MTSVIRRPQ-
EDDnp by both mK1 and rK1 (Table 1), which is in accordance
with the time course for hydrolysis of the bradykinin-containing
fragments of mouse and rat kininogens (Figures 1 and 2). mK1
hydrolysed Abz-GFSPFRSVTVQ-EDDnp (mouse sequence)
c© 2004 Biochemical Society
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with higher kcat/Km values when compared with rK1 or hK1,
indicating a clear species specificity. Hydrolysis of the peptides
Abz-MTEMARRPQ-EDDnp and Abz-MTSVIRRPQ-EDDnp
was also species-specific, since the respective kcat/Km values are
higher for the substrate sequence derived from the kininogen of
the same species, although they were poorer substrates for
all the three assayed kallikreins. Sueyoshi et al. [20] reported
a higher kininogenase activity of mK1 compared with other
kallikreins using a low-molecular-mass mouse kininogen isolated
from the ascitic fluid of sarcoma 180 tumour-bearing mice as
the substrate. Sueyoshi et al. [20] suggested that this particular
species specificity of mK1 was based on its ability to hydrolyse
Boc-MAR-MCA (where Boc stands for t-butoxycarbonyl), which
contains the three amino acids immediately downstream of the
bradykinin sequence in mouse kininogen, with kcat/Km values
approx. 100 times higher than that of pK1. Our results did not show
such a large difference for the hydrolysis by rodent kallikreins of
the Arg–Arg bond on the N-terminal side of bradykinin compared
with the efficient hydrolytic activity on the Arg–Ser bond at the
C-terminal site of bradykinin. It is noteworthy that the capacity
of mK1, rK1 and hK1 to hydrolyse Abz-MTEMARRPQ-EDDnp
at the Arg–Arg bond is probably because the enzyme prefers an
alanine residue at the S2 subsite; in contrast, as mentioned above,
the S2 subsites of hK1 and pK1 have been described to have a
restricted preference for hydrophobic, particularly for aromatic
amino side chains [40,47,48]. The potential ability of hK1 to re-
lease des-[Arg9]bradykinin from rat kininogen was confirmed by
the activity of this enzyme on the peptide Abz-GFSPFRAPRVQ-
EDDnp, which was hydrolysed mainly at the Phe–Arg bond.
Analysis of the products of hydrolysis by hK1 analogue of
this peptide, Abz-GFSPFRASRVQ-EDDnp, where a proline was
substituted with a serine residue, showed that hK1 hydrolysed
preferentially at the Arg–Ala bond (Figure 4). The kcat/Km value
for the hydrolysis of this peptide by hK1 was 32323, which is
almost one order of magnitude higher than that for the hydrolysis
of Abz-GFSPFRAPRVQ-EDDnp by the same enzyme. This result
is further evidence for the role of the proline residue on the
prime side of the substrates in determining both the efficiency
and the peptide bond to be cleaved by hK1 that accepts arginine
or phenylalanine at the S1 subsite.
We further compared the reactivity of hK1 with mK1 and
rK1, examining their hydrolytic activity on two short internally
quenched fluorescent peptides containing a pair of basic amino
acids (Abz-FRR-EDDnp and Abz-FRK-EDDnp), which were
described previously for use with cysteine and serine proteases
[28]. These peptides were hydrolysed by hK1 with very low velo-
city, but bound to the enzyme with K i values in the nM range.
They probably represent model peptides for designing specific and
potent inhibitors for hK1. The high kcat/Km values for the hydro-
lysis of these two peptides by rK1 and mK1 as compared with
the very slow hydrolysis by hK1 (Table 1) was surprising. These
results indicate that rK1 and mK1 have a particular preference for
hydrolysis between basic amino acids, an additional characteristic
of rodent kallikreins that provides them with the ability to release
bradykinin instead of Lys-bradykinin as observed with kallikreins
of other species.
We have previously described the efficiency of hK1 in hydro-
lysing substrates with phenylalanine at the P1 position [29,38]
and observed that the small peptide pFF-MCA (where p stands for
proline in D-diastereo-isomer form) was quite specific for hK1. To
examine this further, the hydrolytic activities of mK1 and rK1 on
pFF-MCA were compared. Poor hydrolysis was observed with
both enzymes, as indicated by the low values of kcat (Table 2).
However, the low Km values for the hydrolysis of this peptide
by mK1 and rK1 are noteworthy, suggesting that these enzymes
Table 2 Kinetic parameters for hydrolysis by mK1, rK1 and hK1 of the
fluorescent peptides pFR-MCA and pFF-MCA
Conditions of hydrolysis were the same as described in Table 1.
Protease mK1 rK1 hK1 mK1 rK1 hK1
Peptidyl-MCA pFR-MCA pFF-MCA
kcat (s−1) 3.18 95.3 3.6 0.085 0.05 12.5
Km (µM) 0.18 1.5 3.1 2.7 1.0 70
kcat/Km 17 666 63 553 1161 30.7 50 179
Table 3 Inhibition constant (Ki) of the previously described inhibitors of
hK1 for mK1 and rK1
Ki (µM)
Peptide rK1 mK1 hK1 Reference
Pac-FSR-EDDnp 3.5 +− 0.1 4.2 +− 0.04 0.70 +− 0.05 [31]
Pac-Aca-SR-NH2 16.9 +− 1.0 12.1 +− 0.01 0.11 +− 0.01 [30]
Ac-kFFPLE-NH2 4.6 +− 0.2 No inhibition 0.029 +− 0.004 [49]
PKSI-527 347 +− 12 48.1 +− 0.08 > 800
can accommodate this peptide, although in an unproductive way,
for catalysis. It appears that the phenylalanine residue at the P1
position does not fit the S1 subsite of mK1 or rK1 as in hK1, which
was confirmed by the very efficient hydrolysis of pFR-MCA (an
excellent substrate for the rodent kallikreins, particularly for rK1;
Table 2).
Inhibition of mK1 and rK1 by inhibitors of hK1
We have described previously inhibitors of hK1 and those that
functioned at the nM range [30,31,49] were assayed as inhibitors
of mK1 and rK1. Table 3 shows the K i values obtained for them
with mK1 and rK1; note that the kinetics of inhibition was of the
competitive type. Pac-FSR-EDDnp (where Pac stands for phenyl-
acetyl) inhibited hK1 with a K i value five times lower than that
for mK1 or rK1. However, this peptide was demonstrated to
have significant inhibitory effects on nociceptive transmission and
inflammatory responses in mice [21]. The peptide Pac-Aca-SR-
NH2 [where Aca stands for (cis, trans)-aminocyclohexyl-alanine]
was described previously as a member of a series of peptides
specially designed to introduce non-natural basic amino acids
at the S1 subsite of hK1 [49]. Pac-Aca-SR-NH2 was resistant
to hydrolysis by hK1, mK1 and rK1, but the K i values for the
inhibition of the last two enzymes were two orders of magnitude
higher than that for hK1. This result indicates that mK1 and rK1
do not accept amino acids bearing a large hydrophobic side chain
at their S1 subsites and do not accept even those bearing a positive
primary amino group in their structure.
The peptide Ac-kFFPLE-NH2 is the best inhibitor of hK1 as
shown in Table 3, but it did not inhibit mK1 at a concentration
below 50 µM, and the K i value for rK1 is two orders of magni-
tude higher. Surprisingly, the peptide Ac-kFFPLE-NH2 also inhi-
bited human plasma kallikrein, with a K i value of 8 nM. This
enzyme is known as a restricted arginyl hydrolase. A specific
inhibitor of human plasma kallikrein, PKSI-527 (trans-4-amino-
methylcyclohexenecarbonyl-L-phenylalanine-4-carboxymethyl-
anilide), was described previously [50]. Its trans-4-aminomethyl-
cyclohexenecarbonyl moiety is supposed to interact with the
c© 2004 Biochemical Society
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negatively charged S1 subsite of human plasma kallikrein, result-
ing in the specificity of the inhibitor. PKSI-527 was assayed
against mK1 and rK1 and the K i values obtained show that it is a
poor inhibitor of these enzymes. Although mK1 and rK1 are
preferentially arginyl hydrolases, similar to plasma kallikrein, the
interactions of mK1 and rK1 with PKSI-527 were clearly very
unfavourable. The trans-4-aminomethylcyclohexenecarbonyl
moiety of this inhibitor is similar to that of Aca in the peptide Pac-
Aca-SR-NH2 discussed above, which was also a poor inhibitor
of mK1 and rK1. The inhibitory activity of the peptide Ac-
kFFPLE-NH2 on hK1 has been interpreted as mainly due to the
presence of glutamic residue at the S3 ′ position [30]. This result
suggests that the negative side chain of glutamic residue could
play the same role as the EDDnp, the NO2 groups of which intro-
duce a strong polarization into this group, generating a negative
moiety that could interact favourably with hK1.
In conclusion, the use of mice or rats as animal models for
studying the kallikrein–kinin system has to take into account the
difference in specificity between rodent enzymes and enzymes
of other mammals, particularly hK1 that can release des-[Arg9]
bradykinin from rat kininogen due to its acceptance of phenyl-
alanine besides arginine residue at the S1 subsite. Inhibitors that
were found to inhibit hK1 in the nM range are weak inhibitors of
mK1 or rK1. The differences described in the present study could
be due to the evolution of rodent glandular kallikreins [9], which
emerged after the separation of primate and rodent lineages and
can result in biological processes specific for each species.
This work was supported by Fundac¸a˜o de Amparo a` Pesquisa do Estado de Sa˜o Paulo
(FAPESP), Conselho Nacional de Desenvolvimento Cient´ıfico e Tecnolo´gico (CNPq) and
Human Frontiers for Science Progress (RG 00043/2000-M). We also thank Dr Michael J.
Blackman for his constructive comments and proofreading the paper.
REFERENCES
1 Clements, J., Hooper, J., Dong, Y. and Harvey, T. (2001) The expanded human kallikrein
(KLK) gene family: genomic organization, tissue-specific expression and potential
functions. Biol. Chem. 382, 5–14
2 Bhoola, K. D., Figueroa, C. D. and Worthy, K. (1992) Bioregulation of kinins: kallikreins,
kininogens, and kininases. Pharmacol. Rev. 44, 1–80
3 Evans, B. A., Drinkwater, C. C. and Richards, R. I. (1987) Mouse glandular kallikrein
genes. Structure and partial sequence analysis of the kallikrein gene locus. J. Biol. Chem.
262, 8027–8034
4 Southard-Smith, M., Pierce, J. C. and MacDonald, R. J. (1994) Physical mapping of the
rat tissue kallikrein family in two gene clusters by analysis of P1 bacteriophage clones.
Genomics 22, 404–417
5 Harvey, T. J., Hooper, J. D., Myers, S. A., Stephenson, S. A., Ashworth, L. K. and
Clements, J. A. (2000) Tissue-specific expression patterns and fine mapping of the
human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. 275, 37397–37406
6 Yousef, G. M., Chang, A., Scorilas, A. and Diamandis, E. P. (2000) Genomic organization
of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys.
Res. Commun. 276, 125–133
7 Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D. and Partin, A. W. (1998) Human
Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but
distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci. 35, 275–368
8 Diamandis, E. P., Yousef, G. M., Luo, L. Y., Magklara, A. and Obiezu, C. V. (2000) The new
human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab.
11, 54–60
9 Olsson, A. Y. and Lundwall, A. (2002) Organization and evolution of the glandular
kallikrein locus in Mus musculus. Biochem. Biophys. Res. Commun. 299, 305–311
10 Evans, B. A., Drinkwater, C. C. and Richards, R. I. (1987) Mouse glandular kallikrein
genes. Structure and partial sequence analysis of the kallikrein gene locus. J. Biol. Chem.
262, 8027–8034
11 van Leeuwen, B. H., Evans, B. A., Tregear, G. W. and Richards, R. I. (1986) Mouse
glandular kallikrein genes. Identification, structure, and expression of the renal kallikrein
gene. J. Biol. Chem. 261, 5529–5535
12 Christiansen, S. C., Proud, D. and Cochrane, C. G. (1987) Detection of tissue kallikrein in
the bronchoalveolar lavage fluid of asthmatic subjects. J. Clin. Invest. 79, 188–197
13 Proud, D., Togias, A., Naclerio, R. M., Crush, S. A., Norman, P. S. and Linchtenstein,
L. M. (1983) Kinins are generated in vivo following nasal airway challenge of allergic
individuals with allergen. J. Clin. Invest. 72, 1678–1685
14 Braumgarten, C. R., Nichols, R. C., Naclerio, R. M. and Proud, D. (1986) Concentrations
of glandular kallikrein in human nasal secretions increase during experimentally induced
allergic rhinitis. J. Immunol. 137, 1323–1328
15 MacDonald, R. J., Margolius, H. S. and Erdo¨s, E. G. (1988) Molecular biology of tissue
kallikrein. Biochem. J. 253, 313–321
16 Axen, R., Gross, E., Witkop, B., Pierce, J. V. and Webster, M. E. (1966) Release of kinin
activity from human kininogens and fresh plasma by cyanogen bromide.
Biochem. Biophys. Res. Commun. 5, 353–357
17 Alhenc-Gelas, F., Marchetti, J., Alegrini, J., Carod, P. and Menard, J. (1981)
Measurement of urinary kallikrein activity. Species differences in kinin production.
Biochim. Biophys. Acta 677, 477–488
18 Kato, H., Enjyoji, K., Miyata, T., Hayashi, I., Oh-ishi, S. and Iwagaga, S. (1985)
Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: direct evidence for
liberation of bradykinin by rat glandular kallikreins. Biochem. Biophys. Res. Commun.
127, 289–295
19 Hosoi, K., Tsunasawa, S., Kurihara, K., Aoyama, H., Ueha, T., Murai, T. and Sakiyama, F.
(1994) Identification of mK1, a true tissue (glandular) kallikrein of mouse submandibular
gland: tissue distribution and a comparison of kinin-releasing activity with other
submandibular kallikreins. J. Biochem. (Tokyo) 115, 137–143
20 Sueyoshi, T., Uwani, M., Itoh, N., Okamoto, H., Muta, T., Tokunaga, F., Takada, K. and
Iwanaga, S. (1990) Cysteine proteinase inhibitor in the ascitic fluid of sarcoma 180
tumor-bearing mice is a low molecular weight kininogen. Partial NH2- and COOH-
terminal sequences and susceptibility to various glandular kallikreins. J. Biol. Chem.
265, 10030–10035
21 Emim, J. A. S., Souccar, C. A., Castro, M. S., Godinho, R. O., Cezari, M. H. S., Juliano, L.
and Lapa, A. J. (2000) Evidence for activation of the tissue kallikrein–kinin system in
nociceptive transmission and inflammatory responses of mice using a specific enzyme
inhibitor. Br. J. Pharmacol. 130, 1099–1107
22 Meneton, P., Bloch-Faure, M., Hagege, A. A., Ruetten, H., Huang, W., Bergaya, S.,
Ceiler, D., Gehring, D., Martins, I., Salmon, G. et al. (2001) Cardiovascular abnormalities
with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad.
Sci. U.S.A. 98, 2634–2639
23 Chao, J. and Chao, L. (1997) Experimental kallikrein gene therapy in hypertension,
cardiovascular and renal diseases. Pharmacol. Res. 35, 517–522
24 Agata, J., Chao, L. and Chao, J. (2002) Kallikrein gene delivery improves cardiac reserve
and attenuates remodeling after myocardial infarction. Hypertension 40, 653–659
25 Silva, Jr, J. A., Arau´jo, R. C., Baltatu, O., Oliveira, S. M., Tschope, C., Fink, E.,
Hoffmann, S., Plehm, R., Chai, K. X., Chao, L. et al. (2000) Reduced cardiac hypertrophy
and altered blood pressure control in transgenic rats with the human tissue kallikrein
gene. FASEB J. 14, 1858–1860
26 Reference deleted
27 Furuto-Kato, S., Matsumoto, A., Kitamura, N. and Nakanishi, S. (1985) Primary structures
of the mRNAs encoding the rat precursors for bradykinin and T-kinin. Structural
relationship of kininogens with major acute phase protein and α1-cysteine proteinase
inhibitor. J. Biol. Chem. 260, 12054–12059
28 Melo, R. L., Alves, L. C., Del Nery, E., Juliano, L. and Juliano, M. A. (2001) Synthesis and
hydrolysis by cysteine and serine proteases of short internally quenched fluorogenic
peptides. Anal. Biochem. 293, 71–77
29 Pimenta, D. C., Juliano, M. A. and Juliano, L. (1997) Hydrolysis of somatostatin by
human tissue kallikrein after the amino acid pair Phe–Phe. Biochem. J. 327, 27–30
30 Pimenta, D. C., Fogac¸a, S. E., Melo, R. L., Juliano, L. and Juliano, M. A. (2003)
Specificity of S′1 and S′2 subsites of human tissue kallikrein using the reactive-centre
loop of kallistatin: the importance of P′1 and P′2 positions in design of inhibitors.
Biochem. J. 371, 1021–1025
31 Portaro, F. C., Cezari, M. H. S., Juliano, M. A., Juliano, L., Walmsley, A. R. and Prado,
E. S. (1997) Design of kallidin-releasing tissue kallikrein inhibitors based on the
specificities of the enzyme’s binding subsites. Biochem. J. 323, 67–71
32 Hirata, I. Y., Cezari, M. H. S., Nakaie, C., Boschcov, P., Ito, A. S., Juliano, M. and
Juliano, L. (1994) Internally quenched fluorogenic protease substrates: solid-phase
synthesis and fluorescence spectroscopy of peptides containing ortho-
aminobenzoyl/dinitrophenyl groups as donor–acceptor pairs. Lett. Peptide Sci. 1,
299–308
33 Hosoi, K., Tanaka, I., Ishii, Y. and Ueha, T. (1983) A new esteroproteinase (proteinase F)
from the submandibular gland of female mice. Biochim. Biophys. Acta 756, 163–170
34 Shimamoto, K., Chao, J. and Margolius, H. S. (1980) The radioimmunoassay of human
urinary kallikrein and comparisons with kallikrein activity measurements.
J. Endocrinol. Metab. 51, 840–848
c© 2004 Biochemical Society
Species specificity of tissue kallikrein 781
35 El Moujahed, A., Brillard-Bourdet, M., Juliano, M. A., Moreau, T., Chagas, J. R.,
Gutman, N., Prado, E. S. and Gauthier, F. (1997) Kininogen-derived fluorogenic
substrates for investigating the vasoactive properties of rat tissue kallikreins –
identification of a T-kinin-releasing rat kallikrein. Eur. J. Biochem. 247, 652–658
36 Sampaio, C. A. M., Sampaio, M. U. and Prado, E. S. (1984) Active-site titration of horse
urinary kallikrein. Hoppe Seyler’s Z. Physiol. Chem. 365, 297–302
37 Wilkinson, G. N. (1961) Statistical estimations in enzyme kinetics. Biochem. J. 80,
324–332
38 Pimenta, D. C., Chao, J., Chao, L., Juliano, M. A. and Juliano, L. (1999) Specificity of
human tissue kallikrein towards substrates containing Phe–Phe pair of amino acids.
Biochem. J. 339, 473–479
39 Chen, Z. and Bode, W. (1983) Refined 2.5 A˚ X-ray crystal structure of the complex formed
by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization,
Patterson search, structure determination, refinement, structure and comparison with its
components and with the bovine trypsin–pancreatic trypsin inhibitor complex.
J. Mol. Biol. 164, 283–311
40 Araujo-Viel, M. S., Juliano, M. A., Oliveira, L. and Prado, E. S. (1988) Horse urinary
kallikrein, II. Effect of subsite interactions on its catalytic activity. Biol. Chem.
Hoppe Seyler 369, 397–401
41 Chagas, J. R., Portaro, F. C., Hirata, I. Y., Almeida, P. C., Juliano, M. A., Juliano, L. and
Prado, E. S. (1995) Determinants of the unusual cleavage specificity of lysyl-bradykinin-
releasing kallikreins. Biochem. J. 306, 63–69
42 Del Nery, E., Chagas, J. R., Juliano, M. A., Prado, E. S. and Juliano, L. (1995) Evaluation
of the extent of the binding site in human tissue kallikrein by synthetic substrates with
sequences of human kininogen fragments. Biochem. J. 312, 233–238
43 Del Nery, E., Chagas, J. R., Juliano, M. A., Juliano, L. and Prado, E. S. (1999)
Comparison of human and porcine tissue kallikrein substrate specificities.
Immunopharmacology 45, 151–157
44 Bourgeois, L., Brillard-Bourdet, M., Deperthes, D., Juliano, M. A., Juliano, L., Tremblay,
R. R., Dube, J. Y. and Gauthier, F. (1977) Serpin-derived peptide substrates for
investigating the substrate specificity of human tissue kallikreins hK1 and hK2.
J. Biol. Chem. 272, 29590–29595
45 Del Nery, E., Juliano, M. A., Lima, A. P., Scharfstein, J. and Juliano, L. (1997)
Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma
cruzi. J. Biol. Chem. 272, 25713–25718
46 Cordova, M., Jara, J., Del Nery, E., Hirata, I. Y., Araujo, M. S., Carmona, A. K., Juliano,
M. A. and Juliano, L. (2001) Characterization of two cysteine proteinases secreted by
Fasciola hepatica and demonstration of their kininogenase activity.
Mol. Biochem. Parasitol. 116, 109–115
47 Chagas, J. R., Hirata, I. Y., Juliano, M. A., Xiong, W., Wang, C., Chao, J., Juliano, L. and
Prado, E. S. (1992) Substrate specificities of tissue kallikrein and T-kininogenase: their
possible role in kininogen processing. Biochemistry 31, 4969–4974
48 Fiedler, F. (1987) Effects of secondary interactions on the kinetics of peptide and peptide
ester hydrolysis by tissue kallikrein and trypsin. Eur. J. Biochem. 163, 303–312
49 Melo, R. L., Barbosa-Pozzo, R. C., Pimenta, D. C., Perissutti, E., Caliendo, G.,
Santagada, V., Juliano, L. and Juliano, M. A. (2001) Human tissue kallikrein S1 subsite
recognition of non-natural basic amino acids. Biochemistry 40, 5226–5232
50 Okada, Y., Tsuda, Y., Tada, M., Wanaka, K., Hijikata-Okunomiya, A., Okamoto, U. and
Okamoto, S. (1999) Development of plasma kallikrein selective inhibitors. Biopolymers
51, 41–50
Received 11 July 2003/23 February 2004; accepted 25 March 2004
Published as BJ Immediate Publication 25 March 2004, DOI 10.1042/BJ20031047
c© 2004 Biochemical Society
